{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:16:34Z","timestamp":1790957794262,"version":"4.1.0"},"publisher-location":"Cham","reference-count":137,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031663550","type":"print"},{"value":"9783031663567","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/7854_2023_452","type":"book-chapter","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T05:01:35Z","timestamp":1699851695000},"page":"21-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Mechanisms of SSRI Therapy and Discontinuation"],"prefix":"10.1007","author":[{"given":"Trevor","family":"Sharp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"3","key":"452_CR1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-199426030-00004","volume":"26","author":"AC Altamura","year":"1994","unstructured":"Altamura AC, Moro AR, Percudani M (1994) Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26(3):201\u2013214","journal-title":"Clin Pharmacokinet"},{"issue":"5697","key":"452_CR2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1101678","volume":"306","author":"MS Ansorge","year":"2004","unstructured":"Ansorge MS, Zhou M, Lira A et al (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306(5697):879\u2013881","journal-title":"Science"},{"issue":"5","key":"452_CR3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K et al (2020) Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 180(5):728\u2013736","journal-title":"JAMA Intern Med"},{"key":"452_CR4","unstructured":"APPG (2018) Antidepressant withdrawal: a survey of patients\u2019 experience. All Party Parliamentary Group for Prescribed Drug Dependence. http:\/\/prescribeddrug.org\/wp-content\/uploads\/2018\/10\/APPG-PDD-Survey-of-antidepressant-withdrawal-experiences.pdf"},{"issue":"9","key":"452_CR5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0166-2236(96)10037-0","volume":"19","author":"F Artigas","year":"1996","unstructured":"Artigas F, Romero L, de Montigny C et al (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19(9):378\u2013383","journal-title":"Trends Neurosci"},{"issue":"7354","key":"452_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E et al (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354):91\u201395","journal-title":"Nature"},{"issue":"3","key":"452_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.yic.0000194377.88330.1d","volume":"21","author":"DS Baldwin","year":"2006","unstructured":"Baldwin DS, Cooper JA, Huusom AK et al (2006) A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21(3):159\u2013169","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"452_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/(SICI)1098-2396(199901)31:1<13::AID-SYN3>3.0.CO;2-Y","volume":"31","author":"CL Barton","year":"1999","unstructured":"Barton CL, Hutson PH (1999) Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B\/D autoreceptors. Synapse 31(1):13\u201319","journal-title":"Synapse"},{"issue":"1","key":"452_CR9","first-page":"e69","volume":"13","author":"NH Bhanji","year":"2006","unstructured":"Bhanji NH, Chouinard G, Kolivakis T et al (2006) Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 13(1):e69\u2013e74","journal-title":"Can J Clin Pharmacol"},{"issue":"12","key":"452_CR10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.biopsych.2005.11.003","volume":"59","author":"JA Blendy","year":"2006","unstructured":"Blendy JA (2006) The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59(12):1144\u20131150","journal-title":"Biol Psychiatry"},{"issue":"7","key":"452_CR11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","volume":"15","author":"P Blier","year":"1994","unstructured":"Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15(7):220\u2013226","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl 4","key":"452_CR12","first-page":"8","volume":"67","author":"P Blier","year":"2006","unstructured":"Blier P, Tremblay P (2006) Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 67(Suppl 4):8\u201313","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"452_CR13","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.neuint.2010.10.001","volume":"57","author":"FJ Bosker","year":"2010","unstructured":"Bosker FJ, Tanke MA, Jongsma ME et al (2010) Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis. Neurochem Int 57(8):948\u2013957","journal-title":"Neurochem Int"},{"issue":"2","key":"452_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-011-2580-1","volume":"221","author":"V Bouet","year":"2012","unstructured":"Bouet V, Klomp A, Freret T et al (2012) Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology (Berl) 221(2):329\u2013339","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"452_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3458.2001.tb00189.x","volume":"7","author":"M Bourin","year":"2001","unstructured":"Bourin M, Chue P, Guillon Y (2001) Paroxetine: a review. CNS Drug Rev 7(1):25\u201347","journal-title":"CNS Drug Rev"},{"key":"452_CR16","doi-asserted-by":"crossref","first-page":"104691","DOI":"10.1016\/j.neubiorev.2022.104691","volume":"138","author":"I Branchi","year":"2022","unstructured":"Branchi I (2022) Plasticity in mental health: a network theory. Neurosci Biobehav Rev 138:104691","journal-title":"Neurosci Biobehav Rev"},{"issue":"7842","key":"452_CR17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J et al (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842):474\u2013479","journal-title":"Nature"},{"issue":"2\u20133","key":"452_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-010-2097-z","volume":"213","author":"GV Carr","year":"2011","unstructured":"Carr GV, Lucki I (2011) The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 213(2\u20133):265\u2013287","journal-title":"Psychopharmacology (Berl)"},{"key":"452_CR19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/PPA.S110632","volume":"10","author":"C Cartwright","year":"2016","unstructured":"Cartwright C, Gibson K, Read J et al (2016) Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence 10:1401\u20131407","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"452_CR20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto PC, Girych M, Fred SM et al (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 184(5):1299\u20131313 e1219","journal-title":"Cell"},{"key":"452_CR21","doi-asserted-by":"crossref","first-page":"1032224","DOI":"10.3389\/fnmol.2022.1032224","volume":"15","author":"P Casarotto","year":"2022","unstructured":"Casarotto P, Umemori J, Castren E (2022) BDNF receptor TrkB as the mediator of the antidepressant drug action. Front Mol Neurosci 15:1032224","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"452_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrn1629","volume":"6","author":"E Castren","year":"2005","unstructured":"Castren E (2005) Is mood chemistry? Nat Rev Neurosci 6(3):241\u2013246","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"452_CR23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.biopsych.2021.05.008","volume":"90","author":"E Castren","year":"2021","unstructured":"Castren E, Monteggia LM (2021) Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry 90(2):128\u2013136","journal-title":"Biol Psychiatry"},{"issue":"10128","key":"452_CR24","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G et al (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357\u20131366","journal-title":"Lancet"},{"issue":"7","key":"452_CR25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/02698811221093032","volume":"36","author":"HM Collins","year":"2022","unstructured":"Collins HM, Pinacho R, Ozdemir D et al (2022) Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice. J Psychopharmacol 36(7):794\u2013805","journal-title":"J Psychopharmacol"},{"key":"452_CR26","doi-asserted-by":"publisher","unstructured":"Collins HM, Ozdemir D, Gullino LS et al (2023a) Rebound activation of 5-HT neurons following SSRI discontinuation. bioRxiv 2023.09.23.558888. https:\/\/doi.org\/10.1101\/2023.09.23.558888","DOI":"10.1101\/2023.09.23.558888"},{"key":"452_CR27","doi-asserted-by":"crossref","unstructured":"Collins HM, Pinacho R, Tam SKE et al (2023b) Continuous home cage monitoring of activity and sleep in mice during repeated paroxetine treatment and discontinuation. Psychopharmacology 240 (11), 2403\u20132418.","DOI":"10.1007\/s00213-023-06442-3"},{"issue":"3","key":"452_CR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000530692","volume":"92","author":"F Cosci","year":"2023","unstructured":"Cosci F, Chouinard VA, Chouinard G (2023) Discontinuation of antidepressant medications: a significant healthcare problem insufficiently addressed by the NICE guidelines. Psychother Psychosom 92(3):148\u2013151","journal-title":"Psychother Psychosom"},{"issue":"8294","key":"452_CR29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(82)90550-5","volume":"2","author":"PJ Cowen","year":"1982","unstructured":"Cowen PJ, Nutt DJ (1982) Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet 2(8294):360\u2013362","journal-title":"Lancet"},{"issue":"1","key":"452_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","volume":"14","author":"MJ Cunningham","year":"2023","unstructured":"Cunningham MJ, Bock HA, Serrano IC et al (2023) Pharmacological mechanism of the non-hallucinogenic 5-HT(2A) agonist ariadne and analogs. ACS Chem Nerosci 14(1):119\u2013135","journal-title":"ACS Chem Nerosci"},{"key":"452_CR31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","volume":"97","author":"J Davies","year":"2019","unstructured":"Davies J, Read J (2019) A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 97:111\u2013121","journal-title":"Addict Behav"},{"issue":"Suppl 4","key":"452_CR32","first-page":"22","volume":"67","author":"PL Delgado","year":"2006","unstructured":"Delgado PL (2006) Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J Clin Psychiatry 67(Suppl 4):22\u201326","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"452_CR33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/archpsyc.1990.01810170011002","volume":"47","author":"PL Delgado","year":"1990","unstructured":"Delgado PL, Charney DS, Price LH et al (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47(5):411\u2013418","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"452_CR34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1399-5618.2002.01203.x","volume":"4","author":"C D'Sa","year":"2002","unstructured":"D'Sa C, Duman RS (2002) Antidepressants and neuroplasticity. Bipolar Disord 4(3):183\u2013194","journal-title":"Bipolar Disord"},{"issue":"69","key":"452_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25690","volume":"25","author":"L Duffy","year":"2021","unstructured":"Duffy L, Clarke CS, Lewis G et al (2021) Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. Health Technol Assess 25(69):1\u201362","journal-title":"Health Technol Assess"},{"issue":"1","key":"452_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-007-1035-1","volume":"199","author":"N Elizalde","year":"2008","unstructured":"Elizalde N, Gil-Bea FJ, Ramirez MJ et al (2008) Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment. Psychopharmacology (Berl) 199(1):1\u201314","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"452_CR37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.biopsych.2012.03.003","volume":"72","author":"M Elsayed","year":"2012","unstructured":"Elsayed M, Banasr M, Duric V et al (2012) Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 72(4):258\u2013265","journal-title":"Biol Psychiatry"},{"issue":"12","key":"452_CR38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.biopsych.2022.10.012","volume":"93","author":"D Erritzoe","year":"2023","unstructured":"Erritzoe D, Godlewska BR, Rizzo G et al (2023) Brain serotonin release is reduced in patients with depression: a [(11)C]Cimbi-36 positron emission tomography study with a d-amphetamine challenge. Biol Psychiatry 93(12):1089\u20131098","journal-title":"Biol Psychiatry"},{"issue":"2","key":"452_CR39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","volume":"84","author":"GA Fava","year":"2015","unstructured":"Fava GA, Gatti A, Belaise C et al (2015) Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 84(2):72\u201381","journal-title":"Psychother Psychosom"},{"key":"452_CR40","doi-asserted-by":"publisher","unstructured":"Fischer AG, Jocham G, Ullsperger M (2014) Dual serotonergic signals: a key to understanding paradoxical effects? Trends Cogn Sci. Epub ahead of print2014\/12\/24. https:\/\/doi.org\/10.1016\/j.tics.2014.11.004","DOI":"10.1016\/j.tics.2014.11.004"},{"issue":"3","key":"452_CR41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0278-5846(82)80180-2","volume":"6","author":"K Fredricson Overo","year":"1982","unstructured":"Fredricson Overo K (1982) Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuropsychopharmacol Biol Psychiatry 6(3):297\u2013309","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"452_CR42","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1476-5381.1995.tb15919.x","volume":"115","author":"SE Gartside","year":"1995","unstructured":"Gartside SE, Umbers V, Hajos M et al (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115(6):1064\u20131070","journal-title":"Br J Pharmacol"},{"issue":"1","key":"452_CR43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcp.2007.06.039","volume":"75","author":"JT Gass","year":"2008","unstructured":"Gass JT, Olive MF (2008) Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75(1):218\u2013265","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"452_CR44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","volume":"45","author":"C Gastaldon","year":"2022","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E et al (2022) Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. Drug Saf 45(12):1539\u20131549","journal-title":"Drug Saf"},{"issue":"10","key":"452_CR45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4088\/JCP.v61n1002","volume":"61","author":"AJ Gelenberg","year":"2000","unstructured":"Gelenberg AJ, Chesen CL (2000) How fast are antidepressants? J Clin Psychiatry 61(10):712\u2013721","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"452_CR46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M et al (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3):439\u2013452","journal-title":"Neuron"},{"issue":"13","key":"452_CR47","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1523\/JNEUROSCI.22-13-05442.2002","volume":"22","author":"C Gras","year":"2002","unstructured":"Gras C, Herzog E, Bellenchi GC et al (2002) A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci 22(13):5442\u20135451","journal-title":"J Neurosci"},{"issue":"12","key":"452_CR48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.mp.4002075","volume":"12","author":"JO Groves","year":"2007","unstructured":"Groves JO (2007) Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12(12):1079\u20131088","journal-title":"Mol Psychiatry"},{"issue":"Suppl 7","key":"452_CR49","first-page":"17","volume":"58","author":"P Haddad","year":"1997","unstructured":"Haddad P (1997) Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 58(Suppl 7):17\u201321. discussion 22","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"452_CR50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S1121189X00006254","volume":"14","author":"PM Haddad","year":"2005","unstructured":"Haddad PM (2005) Do antidepressants cause dependence? Epidemiol Psichiatr Soc 14(2):58\u201362","journal-title":"Epidemiol Psichiatr Soc"},{"key":"452_CR51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1192\/apt.bp.105.001966","volume":"13","author":"PM Haddad","year":"2007","unstructured":"Haddad PM, Anderson IM (2007) Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 13:447\u2013457","journal-title":"Adv Psychiatr Treat"},{"issue":"1\u20132","key":"452_CR52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-2999(00)00723-8","volume":"407","author":"E Hajos-Korcsok","year":"2000","unstructured":"Hajos-Korcsok E, McTavish SF, Sharp T (2000) Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. Eur J Pharmacol 407(1\u20132):101\u2013107","journal-title":"Eur J Pharmacol"},{"key":"452_CR53","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK et al (2020) Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 167:107933","journal-title":"Neuropharmacology"},{"issue":"2","key":"452_CR54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1192\/bjp.bp.108.051193","volume":"195","author":"CJ Harmer","year":"2009","unstructured":"Harmer CJ, Goodwin GM, Cowen PJ (2009) Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195(2):102\u2013108","journal-title":"Br J Psychiatry"},{"issue":"5","key":"452_CR55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","volume":"4","author":"CJ Harmer","year":"2017","unstructured":"Harmer CJ, Duman RS, Cowen PJ (2017) How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 4(5):409\u2013418","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"452_CR56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/hup.2429","volume":"29","author":"BH Harvey","year":"2014","unstructured":"Harvey BH, Slabbert FN (2014) New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 29(6):503\u2013516","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"452_CR57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.biopsych.2004.11.016","volume":"57","author":"G Hayward","year":"2005","unstructured":"Hayward G, Goodwin GM, Cowen PJ et al (2005) Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry 57(5):517\u2013524","journal-title":"Biol Psychiatry"},{"key":"452_CR58","doi-asserted-by":"crossref","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB et al (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 118(17)","DOI":"10.1073\/pnas.2022489118"},{"issue":"1","key":"452_CR59","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/jpet.109.158717","volume":"332","author":"GE Hodes","year":"2010","unstructured":"Hodes GE, Hill-Smith TE, Suckow RF et al (2010) Sex-specific effects of chronic fluoxetine treatment on neuroplasticity and pharmacokinetics in mice. J Pharmacol Exp Ther 332(1):266\u2013273","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"452_CR60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1301399","volume":"33","author":"KA Holick","year":"2008","unstructured":"Holick KA, Lee DC, Hen R et al (2008) Behavioral effects of chronic fluoxetine in BALB\/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33(2):406\u2013417","journal-title":"Neuropsychopharmacology"},{"key":"452_CR501","doi-asserted-by":"crossref","unstructured":"Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I (2019) Lower synaptic density is associated with depression severity and network alterations. Nature Commun. 10(1):1529","DOI":"10.1038\/s41467-019-09562-7"},{"issue":"6","key":"452_CR61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","volume":"6","author":"MA Horowitz","year":"2019","unstructured":"Horowitz MA, Taylor D (2019) Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 6(6):538\u2013546","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"452_CR62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","volume":"37","author":"MA Horowitz","year":"2023","unstructured":"Horowitz MA, Framer A, Hengartner MP et al (2023) Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs 37(2):143\u2013157","journal-title":"CNS Drugs"},{"issue":"2","key":"452_CR63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.mp.4002104","volume":"13","author":"GJ Huang","year":"2008","unstructured":"Huang GJ, Bannerman D, Flint J (2008) Chronic fluoxetine treatment alters behavior, but not adult hippocampal neurogenesis, BALB\/cJ mice. Mol Psychiatry 13(2):119\u2013121","journal-title":"Mol Psychiatry"},{"issue":"6","key":"452_CR64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881119845799","volume":"33","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Hayes J, Goodwin GM et al (2019) Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol 33(6):655\u2013659","journal-title":"J Psychopharmacol"},{"key":"452_CR65","doi-asserted-by":"publisher","unstructured":"Jauhar S, Arnone D, Baldwin DS et al (2023) A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Mol Psychiatry. Epub ahead of print 2023\/06\/16. https:\/\/doi.org\/10.1038\/s41380-023-02095-y","DOI":"10.1038\/s41380-023-02095-y"},{"issue":"5","key":"452_CR66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.neuropharm.2007.12.001","volume":"54","author":"KA Jennings","year":"2008","unstructured":"Jennings KA, Sheward WJ, Harmar AJ et al (2008) Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology 54(5):776\u2013783","journal-title":"Neuropharmacology"},{"issue":"4","key":"452_CR67","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1471-4159.2010.07001.x","volume":"115","author":"KA Jennings","year":"2010","unstructured":"Jennings KA, Lesch KP, Sharp T et al (2010) Non-linear relationship between 5-HT transporter gene expression and frequency sensitivity of 5-HT signals. J Neurochem 115(4):965\u2013973","journal-title":"J Neurochem"},{"issue":"8","key":"452_CR68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1017\/S1461145711001258","volume":"15","author":"KA Jennings","year":"2012","unstructured":"Jennings KA, Licht CL, Bruce A et al (2012) Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT(4) receptor levels. Int J Neuropsychopharmacol 15(8):1099\u20131107","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"452_CR69","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1176\/appi.ajp.2018.18060692","volume":"175","author":"MK Jha","year":"2018","unstructured":"Jha MK, Rush AJ, Trivedi MH (2018) When discontinuing SSRI antidepressants is a challenge: management tips. Am J Psychiatry 175(12):1176\u20131184","journal-title":"Am J Psychiatry"},{"key":"452_CR70","doi-asserted-by":"publisher","unstructured":"Johnston JN, Kadriu B, Kraus C et al (2023) Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology. Epub ahead of print 2023\/06\/21. https:\/\/doi.org\/10.1038\/s41386-023-01632-1","DOI":"10.1038\/s41386-023-01632-1"},{"issue":"3","key":"452_CR71","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.neuroimage.2007.10.016","volume":"39","author":"H Jovanovic","year":"2008","unstructured":"Jovanovic H, Lundberg J, Karlsson P et al (2008) Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39(3):1408\u20131419","journal-title":"Neuroimage"},{"issue":"9","key":"452_CR72","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/nm.2886","volume":"18","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Voleti B, Hajszan T et al (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18(9):1413\u20131417","journal-title":"Nat Med"},{"issue":"5","key":"452_CR73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.molmed.2023.02.003","volume":"29","author":"JW Kim","year":"2023","unstructured":"Kim JW, Suzuki K, Kavalali ET et al (2023) Bridging rapid and sustained antidepressant effects of ketamine. Trends Mol Med 29(5):364\u2013375","journal-title":"Trends Mol Med"},{"issue":"5","key":"452_CR74","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein ME, Chandra J, Sheriff S et al (2020) Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A 117(5):2656\u20132662","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"452_CR75","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nrd2828","volume":"8","author":"GF Koob","year":"2009","unstructured":"Koob GF, Kenneth Lloyd G, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 8(6):500\u2013515","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"452_CR76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"TR Kosten","year":"2002","unstructured":"Kosten TR, George TP (2002) The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1(1):13\u201320","journal-title":"Sci Pract Perspect"},{"issue":"2","key":"452_CR77","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/bjp.2008.243","volume":"155","author":"M Kreilgaard","year":"2008","unstructured":"Kreilgaard M, Smith DG, Brennum LT et al (2008) Prediction of clinical response based on pharmacokinetic\/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 155(2):276\u2013284","journal-title":"Br J Pharmacol"},{"issue":"11","key":"452_CR78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH et al (2022) The neural basis of psychedelic action. Nat Neurosci 25(11):1407\u20131419","journal-title":"Nat Neurosci"},{"key":"452_CR79","doi-asserted-by":"crossref","first-page":"5857243","DOI":"10.1155\/2019\/5857243","volume":"2019","author":"AK Lagas","year":"2019","unstructured":"Lagas AK, Black JM, Russell BR et al (2019) The effect of combined patching and citalopram on visual acuity in adults with amblyopia: a randomized, crossover, placebo-controlled trial. Neural Plast 2019:5857243","journal-title":"Neural Plast"},{"issue":"11","key":"452_CR80","first-page":"CD009286","volume":"11","author":"LA Legg","year":"2021","unstructured":"Legg LA, Rudberg AS, Hua X et al (2021) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 11(11):CD009286","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"452_CR81","doi-asserted-by":"crossref","first-page":"fcz025","DOI":"10.1093\/braincomms\/fcz025","volume":"1","author":"A Lerner","year":"2019","unstructured":"Lerner A, Klein M (2019) Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 1(1):fcz025","journal-title":"Brain Commun"},{"issue":"2","key":"452_CR82","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","volume":"160","author":"R Levinson-Castiel","year":"2006","unstructured":"Levinson-Castiel R, Merlob P, Linder N et al (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160(2):173\u2013176","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"452_CR83","doi-asserted-by":"crossref","first-page":"112203","DOI":"10.1016\/j.celrep.2023.112203","volume":"42","author":"V Lewis","year":"2023","unstructured":"Lewis V, Bonniwell EM, Lanham JK et al (2023) A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep 42(3):112203","journal-title":"Cell Rep"},{"key":"452_CR84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuroscience.2012.09.057","volume":"251","author":"P Licznerski","year":"2013","unstructured":"Licznerski P, Duman RS (2013) Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 251:33\u201350","journal-title":"Neuroscience"},{"issue":"1","key":"452_CR85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41398-019-0476-8","volume":"9","author":"J Lima","year":"2019","unstructured":"Lima J, Sharp T, Bannerman DM et al (2019) Enhanced discriminative aversive learning and amygdala responsivity in 5-HT transporter mutant mice. Transl Psychiatry 9(1):139","journal-title":"Transl Psychiatry"},{"issue":"3","key":"452_CR86","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0306-4522(94)00550-O","volume":"65","author":"N Lindefors","year":"1995","unstructured":"Lindefors N, Brodin E, Metsis M (1995) Spatiotemporal selective effects on brain-derived neurotrophic factor and trkB messenger RNA in rat hippocampus by electroconvulsive shock. Neuroscience 65(3):661\u2013670","journal-title":"Neuroscience"},{"issue":"1","key":"452_CR87","first-page":"13","volume":"22","author":"J Littleton","year":"1998","unstructured":"Littleton J (1998) Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 22(1):13\u201324","journal-title":"Alcohol Health Res World"},{"issue":"11","key":"452_CR88","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23(11):3170\u20133182","journal-title":"Cell Rep"},{"issue":"5","key":"452_CR89","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1037\/0735-7044.115.5.1145","volume":"115","author":"GM MacQueen","year":"2001","unstructured":"MacQueen GM, Ramakrishnan K, Croll SD et al (2001) Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav Neurosci 115(5):1145\u20131153","journal-title":"Behav Neurosci"},{"issue":"7","key":"452_CR90","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D et al (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44(7):1328\u20131334","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"452_CR91","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.biopsych.2021.01.010","volume":"90","author":"JE Malberg","year":"2021","unstructured":"Malberg JE, Hen R, Madsen TM (2021) Adult neurogenesis and antidepressant treatment: the surprise finding by Ron Duman and the field 20 years later. Biol Psychiatry 90(2):96\u2013101","journal-title":"Biol Psychiatry"},{"issue":"5874","key":"452_CR92","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1150516","volume":"320","author":"JF Maya Vetencourt","year":"2008","unstructured":"Maya Vetencourt JF, Sale A, Viegi A et al (2008) The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320(5874):385\u2013388","journal-title":"Science"},{"issue":"6","key":"452_CR93","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","volume":"21","author":"TD McClure-Begley","year":"2022","unstructured":"McClure-Begley TD, Roth BL (2022) The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov 21(6):463\u2013473","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"452_CR94","first-page":"CD009286","volume":"11","author":"GE Mead","year":"2012","unstructured":"Mead GE, Hsieh CF, Lee R et al (2012) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 11(11):CD009286","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"452_CR95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S et al (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826\u2013835","journal-title":"Am J Psychiatry"},{"issue":"6","key":"452_CR96","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA et al (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 26(6):1032\u20131041","journal-title":"Nat Neurosci"},{"key":"452_CR97","doi-asserted-by":"publisher","unstructured":"Moncrieff J, Cooper RE, Stockmann T et al (2022) The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. Epub ahead of print 2022\/07\/20. https:\/\/doi.org\/10.1038\/s41380-022-01661-0","DOI":"10.1038\/s41380-022-01661-0"},{"issue":"4 Suppl","key":"452_CR98","first-page":"S33","volume":"11","author":"M Mucci","year":"1997","unstructured":"Mucci M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11(4 Suppl):S33\u2013S37","journal-title":"J Psychopharmacol"},{"issue":"1","key":"452_CR99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JCP.0b013e3181c8ae80","volume":"30","author":"Y Murata","year":"2010","unstructured":"Murata Y, Kobayashi D, Imuta N et al (2010) Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol 30(1):11\u201317","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"452_CR100","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/npp.2015.335","volume":"41","author":"AG Nackenoff","year":"2016","unstructured":"Nackenoff AG, Moussa-Tooks AB, McMeekin AM et al (2016) Essential contributions of serotonin transporter inhibition to the acute and chronic actions of fluoxetine and citalopram in the SERT Met172 mouse. Neuropsychopharmacology 41(7):1733\u20131741","journal-title":"Neuropsychopharmacology"},{"issue":"10 Pt B","key":"452_CR101","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.bbamem.2015.03.020","volume":"1848","author":"RM Navari","year":"2015","unstructured":"Navari RM (2015) 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta 1848(10 Pt B):2738\u20132746","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"452_CR102","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","volume":"15","author":"M Nibuya","year":"1995","unstructured":"Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15(11):7539\u20137547","journal-title":"J Neurosci"},{"key":"452_CR103","doi-asserted-by":"crossref","first-page":"107703","DOI":"10.1016\/j.neuropharm.2019.107703","volume":"167","author":"Y Ohmura","year":"2020","unstructured":"Ohmura Y, Tsutsui-Kimura I, Sasamori H et al (2020) Different roles of distinct serotonergic pathways in anxiety-like behavior, antidepressant-like, and anti-impulsive effects. Neuropharmacology 167:107703","journal-title":"Neuropharmacology"},{"issue":"3","key":"452_CR104","first-page":"1305","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ et al (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283(3):1305\u20131322","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"452_CR105","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.biopsych.2005.08.010","volume":"59","author":"RV Parsey","year":"2006","unstructured":"Parsey RV, Kent JM, Oquendo MA et al (2006) Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 59(9):821\u2013828","journal-title":"Biol Psychiatry"},{"issue":"3","key":"452_CR106","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2003.09.017","volume":"46","author":"Q Pei","year":"2004","unstructured":"Pei Q, Tordera R, Sprakes M et al (2004) Glutamate receptor activation is involved in 5-HT2 agonist-induced arc gene expression in the rat cortex. Neuropharmacology 46(3):331\u2013339","journal-title":"Neuropharmacology"},{"key":"452_CR107","first-page":"45","volume":"4","author":"T Renoir","year":"2013","unstructured":"Renoir T (2013) Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 4:45","journal-title":"Front Pharmacol"},{"issue":"7","key":"452_CR108","doi-asserted-by":"crossref","first-page":"e22133","DOI":"10.1371\/journal.pone.0022133","volume":"6","author":"T Renoir","year":"2011","unstructured":"Renoir T, Zajac MS, Du X et al (2011) Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PloS One 6(7):e22133","journal-title":"PloS One"},{"issue":"23","key":"452_CR109","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1523\/JNEUROSCI.0950-04.2004","volume":"24","author":"M Riad","year":"2004","unstructured":"Riad M, Zimmer L, Rbah L et al (2004) Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. J Neurosci 24(23):5420\u20135426","journal-title":"J Neurosci"},{"issue":"4","key":"452_CR110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","volume":"12","author":"HG Ruhe","year":"2007","unstructured":"Ruhe HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12(4):331\u2013359","journal-title":"Mol Psychiatry"},{"issue":"5634","key":"452_CR111","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","volume":"301","author":"L Santarelli","year":"2003","unstructured":"Santarelli L, Saxe M, Gross C et al (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301(5634):805\u2013809","journal-title":"Science"},{"issue":"6","key":"452_CR112","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/mp.2015.69","volume":"21","author":"L Schmaal","year":"2016","unstructured":"Schmaal L, Veltman DJ, van Erp TG et al (2016) Subcortical brain alterations in major depressive disorder: findings from the ENIGMA major depressive disorder working group. Mol Psychiatry 21(6):806\u2013812","journal-title":"Mol Psychiatry"},{"issue":"1","key":"452_CR113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/13543784.6.1.65","volume":"6","author":"E Schweizer","year":"1997","unstructured":"Schweizer E, Thielen RJ, Frazer A (1997) Venlafaxine:a novel antidepressant compound. Expert Opin Investig Drugs 6(1):65\u201378","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"452_CR114","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1523\/JNEUROSCI.2238-16.2016","volume":"37","author":"A Sengupta","year":"2017","unstructured":"Sengupta A, Bocchio M, Bannerman DM et al (2017) Control of amygdala circuits by 5-HT neurons via 5-HT and glutamate cotransmission. J Neurosci 37(7):1785\u20131796","journal-title":"J Neurosci"},{"issue":"16","key":"452_CR115","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I et al (2021) Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109(16):2535\u20132544 e2534","journal-title":"Neuron"},{"key":"452_CR116","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/7854_2012_216","volume":"14","author":"T Sharp","year":"2013","unstructured":"Sharp T (2013) Molecular and cellular mechanisms of antidepressant action. Curr Top Behav Neurosci 14:309\u2013325","journal-title":"Curr Top Behav Neurosci"},{"key":"452_CR117","doi-asserted-by":"crossref","first-page":"108155","DOI":"10.1016\/j.neuropharm.2020.108155","volume":"177","author":"T Sharp","year":"2020","unstructured":"Sharp T, Barnes NM (2020) Central 5-HT receptors and their function; present and future. Neuropharmacology 177:108155","journal-title":"Neuropharmacology"},{"issue":"1","key":"452_CR118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coph.2011.02.003","volume":"11","author":"T Sharp","year":"2011","unstructured":"Sharp T, Cowen PJ (2011) 5-HT and depression: is the glass half-full? Curr Opin Pharmacol 11(1):45\u201351","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"452_CR119","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/VES-130494","volume":"23","author":"E Soto","year":"2013","unstructured":"Soto E, Vega R, Sesena E (2013) Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res 23(3):119\u2013137","journal-title":"J Vestib Res"},{"issue":"8","key":"452_CR120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2215-0366(15)00232-1","volume":"2","author":"M Spies","year":"2015","unstructured":"Spies M, Knudsen GM, Lanzenberger R et al (2015) The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry 2(8):743\u2013755","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"452_CR121","first-page":"470","volume":"18","author":"L Staner","year":"1995","unstructured":"Staner L, Kerkhofs M, Detroux D et al (1995) Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 18(6):470\u2013477","journal-title":"Sleep"},{"issue":"24","key":"452_CR122","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1016\/S0024-3205(02)02138-0","volume":"71","author":"C Stenfors","year":"2002","unstructured":"Stenfors C, Ross SB (2002) Evidence for involvement of 5-hydroxytryptamine(1B) autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci 71(24):2867\u20132880","journal-title":"Life Sci"},{"key":"452_CR123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbr.2013.02.015","volume":"245","author":"T Strekalova","year":"2013","unstructured":"Strekalova T, Anthony DC, Dolgov O et al (2013) The differential effects of chronic imipramine or citalopram administration on physiological and behavioral outcomes in naive mice. Behav Brain Res 245:101\u2013106","journal-title":"Behav Brain Res"},{"issue":"6","key":"452_CR124","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1038\/s41380-022-01520-y","volume":"27","author":"AN Tartt","year":"2022","unstructured":"Tartt AN, Mariani MB, Hen R et al (2022) Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications. Mol Psychiatry 27(6):2689\u20132699","journal-title":"Mol Psychiatry"},{"issue":"18","key":"452_CR125","doi-asserted-by":"crossref","first-page":"PL187-192","DOI":"10.1016\/0024-3205(93)90116-K","volume":"52","author":"JH Trouvin","year":"1993","unstructured":"Trouvin JH, Gardier AM, Chanut E et al (1993) Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. Life Sci 52(18):PL187-192","journal-title":"Life Sci"},{"issue":"9","key":"452_CR126","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/pcn.12683","volume":"72","author":"J Umemori","year":"2018","unstructured":"Umemori J, Winkel F, Didio G et al (2018) iPlasticity: induced juvenile-like plasticity in the adult brain as a mechanism of antidepressants. Psychiatry Clin Neurosci 72(9):633\u2013653","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6633","key":"452_CR127","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C et al (2023) Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379(6633):700\u2013706","journal-title":"Science"},{"key":"452_CR128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-pharmtox-010611-134540","volume":"53","author":"V Vialou","year":"2013","unstructured":"Vialou V, Feng J, Robison AJ et al (2013) Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 53:59\u201387","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"452_CR129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnana.2015.00023","volume":"9","author":"E Vigneault","year":"2015","unstructured":"Vigneault E, Poirel O, Riad M et al (2015) Distribution of vesicular glutamate transporters in the human brain. Front Neuroanat 9:23","journal-title":"Front Neuroanat"},{"issue":"5","key":"452_CR130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0000000000001460","volume":"41","author":"CH Vinkers","year":"2021","unstructured":"Vinkers CH, Ruhe HG, Penninx BW (2021) Antidepressant discontinuation: in need of scientific evidence. J Clin Psychopharmacol 41(5):512\u2013515","journal-title":"J Clin Psychopharmacol"},{"issue":"17","key":"452_CR131","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A et al (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897\u20133902","journal-title":"Neuroreport"},{"issue":"2","key":"452_CR132","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s11033-022-08110-9","volume":"50","author":"HT Warlick","year":"2023","unstructured":"Warlick HT, Leon L, Patel R et al (2023) Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model. Mol Biol Rep 50(2):1765\u20131784","journal-title":"Mol Biol Rep"},{"issue":"1","key":"452_CR133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coph.2007.10.013","volume":"8","author":"JL Warner-Schmidt","year":"2008","unstructured":"Warner-Schmidt JL, Duman RS (2008) VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 8(1):14\u201319","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"452_CR134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.jcp.0000104907.75206.c2","volume":"24","author":"JF Wernicke","year":"2004","unstructured":"Wernicke JF, Adler L, Spencer T et al (2004) Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit\/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 24(1):30\u201335","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"452_CR135","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205\u20131215","journal-title":"Am J Psychiatry"},{"issue":"10","key":"452_CR136","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamapsychiatry.2015.1472","volume":"72","author":"KA Yonkers","year":"2015","unstructured":"Yonkers KA, Kornstein SG, Gueorguieva R et al (2015) Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry 72(10):1037\u20131044","journal-title":"JAMA Psychiatry"}],"container-title":["Current Topics in Behavioral Neurosciences","Emerging Neurobiology of Antidepressant Treatments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2023_452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T20:47:17Z","timestamp":1721854037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2023_452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031663550","9783031663567"],"references-count":137,"URL":"https:\/\/doi.org\/10.1007\/7854_2023_452","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"14 November 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}